Printer Friendly

Mechanism of Reduced Susceptibility to Fosfomycin in Escherichia coli Clinical Isolates.

1. Introduction

Escherichia coli is a causative agent of uncomplicated urinary tract infections in immunocompetent hosts and opportunistic infections in immunocompromised hosts. In recent years, fluoroquinolone-resistant and/or extended spectrum [beta]-lactamase- (ESBL-) producing E. coli strains have been frequently isolated from such patients [1-4]. In addition, these E. coli resistant strains occasionally show cross-resistance to aminoglycosides [5]. Thus, these multidrug-resistant E. coli have an impact on the selection of therapeutically effective drugs.

Because of this serious concern, the use of fosfomycin (FOM), an antibiotic as a bacterial cell wall synthesis inhibitor developed 40 years ago, has been reevaluated against drug-resistant bacteria, especially E. coli [6, 7]. Since FOM has a unique mode of action that differed from other antibiotics, it is expected to display little cross-resistance to other antimicrobial agents. E. coli is the most frequent causative pathogenic bacterium of acute cystitis [8, 9]. For instance, trimethoprim/sulfamethoxazole and FOM are recommended as the first-line treatment in acute uncomplicated urinary tract infections according to the US guideline [10]. On the other hand, the guideline of the Japanese Association for Infectious Diseases and Japan Society for Chemotherapy recommends fluoroquinolones as the first-line drug and FOM as the second-line drug [11].

FOM inhibits UDP-N-acetylglucosamine enolpyruvyl transferase (MurA), an enzyme involved in the synthesis of the essential peptidoglycan component, N-acetylmuramic acid [12]. FOM is incorporated into the bacterial cells via glucose-6-phosphate (G6P) transporter UhpT and sn-glycerol-3-phosphate (G3P) transporter GlpT [13,14]. UhpT is upregulated by exogenously added G6P [15-17]. It is thus recommended that the addition of G6P to a growth medium is used in the measurement of FOM MIC.

High resistance to FOM primarily occurs by the acquisition of glutathione S-transferase genes, such as fosA, fosA2 to fosA5, fosC, fosC2,fosB, fosB2, fosX, andfosKP96 found in various bacteria [19, 21-26], and mutation(s) in murA gene [18, 24, 27,28]. Furthermore, mutations in the transporter genes, uhpT and glpT, and genes encoding proteins regulating uhpT expression, such as uhpA, reduce the susceptibility to FOM [18, 19, 27-29]. In addition, expression levels of UhpT and GlpT are positively regulated by cyclic AMP (cAMP) [16,17]. The levels of cAMP are controlled by phosphoenolpyruvate-protein phosphotransferase I, encoded by ptsI, and adenyl cyclase, encoded by cya A, and mutations in these genes result in reduced susceptibility to FOM [29-31].

Nevertheless, several surveillance studies report that the rate of emergence of E. coli isolates showing FOM resistance or reduced FOM susceptibility has been markedly low [7, 9, 32]. Although spontaneously mutational rate to acquire FOM resistance is high, FOM resistance confers biological costs, such as reduced cell growth rate in Gram-negative bacteria [29, 33]. This indicates that FOM continues to be an effective agent against E. coli infections. However, the overall up-to-date status of FOM resistance needs to be continuously surveyed and its molecular characteristics have to be understood to prevent future emergence and increase of multidrug-resistant E. coli with FOM resistance in the clinic. In this study, we screened E. coli clinical isolates from Japan showing resistance or reduced susceptibility to FOM and identified the molecular mechanisms of their reduced susceptibility.

2. Materials and Methods

2.1. Bacterial Strains. E. coli clinical isolates (211 strains) were collected in the years 2008-2009 as described previously [4, 5]. These were identified and stocked in Sapporo Clinical Laboratory, Inc. (Sapporo, Japan). These strains were collected from a variety of clinical specimens in almost entire area of Hokkaido Prefecture, Japan. This study was

approved by the review boards of the relevant institutions. The strains were isolated from the following clinical specimens: urine (n = 87, 41.0%), catheter urine (n = 76, 35.8%), sputum (n = 15, 7.1%), stool (n = 7, 3.3%), vaginal secretion (n = 6, 2.8%), pus (n = 3, 1.4%), aspiration tube (n = 3, 1.4%), drainage tube, intravenous hyperalimentation catheter tube, rhinorrhea (two strains from each type of specimen, 0.9%), ascites, anal gland fluid, decubitus, injury site, intestinal juice, stoma, PEG insertion site, pharynx fluid, and synovial fluid (one strain from each type of specimen, 0.5%). Identification was performed using the MicroScan WalkAway 96 system (Beckman Coulter, Tokyo, Japan). E. coli strain ATCC25922 was obtained from American Type Culture Collection (Manassas, VA).

2.2. Antibiotic Susceptibility. FOM, imipenem (IPM), and ceftazidime (CAZ) were provided by Meiji Seika Pharma (Tokyo, Japan), MSD (Tokyo, Japan), and Glaxo SmithKline (Tokyo, Japan), respectively. Minimum inhibitory concentration (MIC) was determined by broth microdilution method or agar plate dilution method according to the recommendations of the Clinical and Laboratory Standards Institute (CLSI) with breakpoints according to CLSI guidelines [34]. The MIC of FOM was measured by the agar dilution method in the absence of G6P, in the presence of 25 [micro]g/mL G6P, and in the presence of 25 [micro]g/mL G6P and 2 mM cAMP

2.3. Measurements of Carbohydrate Phosphate Transporter Activity. E. coli cells were cultured for 24 h in Muller-Hinton broth and harvested by centrifugation. The cell pellet was washed twice with saline. E. coli cell suspension with saline was then used to inoculate to M9 minimum salt (Becton Dickinson, Franklin Lakes, NJ) agar supplemented with 0.2% G6P or 0.2% G3P [18]. Cell growth was observed after incubation for 24 h in the case of G6P and for 48 h in the case of G3P

2.4. Genetic Analysis. DNA was isolated using DNeasy Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Polymerase chain reaction (PCR) was performed using KAPATaq Extra HotStart Ready Mix with dye (NIPPON Genetics, Tokyo, Japan). Serogroups [35, 36] and phylogenetic groups [37] were determined by PCR. Multilocus sequence typing (MLST) was determined according to Tartof et al. [38]. Genes of fosA, fosA3, fosC2 [22], fosB2, fosC, fosX [26], fosB [21], fosA3/4 [25], and fosKP96 [24] were detected by PCR using the primers described previously. Gene of fosA5 was detected by PCR using primer set: 5'-ACTGAATCACCTGACCCTGG-3' and 5'-CGCATAATGGGTGTAGTCGC-3'. Full nucleotide sequences of six genes (murA, uhpT, glpT, uhpA, ptsI, and cyaA) were determined by a combination of direct sequencing and primer walking with the respective PCR products. PCR primer sequences are given in Table 1. The sequencing was performed with Big Dye Terminator Kit version 3.1 and 3730xI DNA analyzer (Applied Biosystems, Carlsbad, CA) at Hokkaido System Science (Sapporo, Japan).

2.5. Real-Time Reverse-Transcription (RT) PCR. E. coli cells were grown for 24 h in Luria-Bertani (LB) broth, and the cells were harvested and washed twice with M9 minimum salt solution. The suspended cells were used to inoculate to M9 minimum salt solution with or without 0.2% G6P supplementation and incubated for 30 min at 37[degrees]C. RNA was isolated from the cells using RNeasy Plus Mini Kit (Qiagen) according to the manufacturer's instructions. cDNA was prepared from the RNA using SuperScript III First Strand Synthesis Kit (Invitrogen, Carlsbad, CA) and random hexamer oligonucleotide primers. mRNA levels of uhpT and rpoD were quantified using QuantiFast SYBR Green PCR Mastermix (Qiagen) by LightCycler LC480 (Roche, Basel, Switzerland) with the cDNA as a template. PCR primers were given in Table 1. Levels of uhpT transcript were calculated by [2.sup.-[DELTA][DELTA]ct] method, and data were normalized to the levels of the house-keeping gene rpoD mRNA.

3. Results

3.1. Antibiotic Susceptibility. Antibiotic susceptibility was examined for 211 E. coli clinical isolates. MICs were determined by broth microdilution method for LVX, GEN, IPM, and CAZ and by agar plate dilution method for FOM (Table 2). The distribution of FOM MIC was shown in Figure 1. Three strains (1.4%) were not susceptible, including resistant and intermediate. Furthermore, seven strains (3%) with elevated FOM MIC ([greater than or equal to] 8 [micro]g/mL, [less than or equal to]64 [micro]g/mL) were observed out of normal distribution of the susceptible strains. FOM MICs of these ten strains were not affected by the presence or absence of G6P. By contrast, other susceptible strains (MIC [less than or equal to] 2 [micro]g/mL) showed an increase of FOM MICs in the absence of G6P (Table 3). Susceptibility to other antibiotics was examined for strains with reduced susceptibility to FOM (Table 2). LVX-resistant strains comprised 50% and GEN-resistant strains comprised 30% of these strains. IPM-resistant and CAZ-resistant strains were not observed; however 20% strains shared CTX-M-type ESBL genes. The occurrence of antimicrobial nonsusceptibility was not significantly high compared to total strains examined (data not shown). Genotypes (i.e., phylogenetic groups and MLST) and O-serogroups of these strains were variable (Table 3).

3.2. Analysis of Genes Associated with FOM Sensitivity. We examined molecular mechanisms underlying the reduction of FOM sensitivity (MIC [greater than or equal to] 8 [micro]g/mL). First, genes encoding FOM-modifying enzymes were investigated. None of the following were detected in the strains examined: fosA, fosA2 to fosA5, fosC, fosC2, fosB, fosB2, fosX, and fosKP96 (data not shown). Next, nucleotide sequences of murA, uhpT, uhpA, glpT, ptsI, and cyaA genes were determined (Table 3). No murA coding sequence mutations that would result in changes of amino acid residues in MurA were observed. A resistant strain (SRE257) and an intermediate-resistant strain (SRE91) had mutations in the genes that would result in deletions of a part of amino acid residues in UhpA and GlpT, respectively. In another intermediate-resistant strain (SRE49), uhpA and uhpT were not detected by PCR amplification with two distinct primer pairs ("full" and "partial" in Table 1). In one strain with MIC 32 [micro]g/mL (SRE252), cyaA was not detectable by PCR. All strains with reduced FOM MIC ([greater than or equal to] 8 [micro]g/mL) except one (SRE29), had several mutations in one or more genes leading to amino acid deletion or point mutation(s) of amino acid residues, compared with other susceptible strains.

3.3. Function and Expression of Carbohydrate Phosphate Transporters. To determine the activity of UhpT and GlpT, we examined cell growth in M9 minimum salt solution supplemented with G6P or G3P. Nine of ten strains with FOM MIC [greater than or equal to] 8 [micro]g/mL did not grow within 24 h on G6P-containing M9 minimum salt agar. On the other hand, only three of ten strains did not grow in the presence of G3P (Table 3), and the two strains (SRE91 and SRE252) showed reduced MIC to FOM by addition of cAMP. This suggested that these two strains shared insufficient intracellular concentration of cAMP for full expression of GlpT and/or UhpT. These results suggested that FOM incorporation through the UhpT system is involved to a greater extent in the reduction of E. coli FOM compared to the GlpT system.

Expression of UhpT is induced by G6P [15-17]. We therefore determined uhpT gene induction by G6P using quantitative RT-PCR analysis (Table 3 and Figure 2). In strains with FOM MIC < 1 [micro]g/mL, uhpT expression was strongly induced (190- to 730-fold) by G6P. By contrast, in eight of ten strains with FOM MIC [greater than or equal to] 8 [micro]g/mL, the uhpT induction was markedly lower (0.56- to 3.8-fold) or no uhpT signal was amplified by PCR. Of the remaining two strains, we observed a high induction (200-fold) of uhpT expression by G6P in SRE253 strain; however, the strain did not grow on G6P-containing M9 minimum agar. High induction (1200-fold) of uhpT by G6P was observed in SRE29 strain, and the strain grew on G6P-containing M9 minimum agar; however, it showed reduced susceptibility to FOM (MIC 32 [micro]g/mL). These results indicated that G6P-dependent growth lacked in most strains with reduced susceptibility to FOM because of lack of uhpT or a markedly reduced uhpT induction by G6P. However, the changes in uhpT expression and UhpT activity did not account for the reduced FOM susceptibility of a few strains (Figure 2).

4. Discussion

The frequency of FOM resistance has been recognized to be low. And it has been expected that the frequency of cross-resistance of FOM and other antibiotics is very low because of a unique mode of action. However, several reports examined FOM resistance in ESBL-producing E. coli [19, 23, 24, 28]. A report indicates that FOM-resistant and intermediate E. coli are more frequently resistant to other types of antimicrobials than FOM-susceptible strains [28]. These reports suggest the importance for surveillance of FOM-resistant E. coli, particularly for focus on their cross-resistance of FOM in multidrug resistance.

In this study, only one resistant and two intermediate strains were found among 211 clinical isolates from Japan (Figure 1). This indicated that FOM was a promising candidate agent against E. coli infections as generally described. However, we found seven strains susceptible according to the CLST breakpoint but reduced susceptibility (MIC [greater than or equal to] 8 [micro]g/mL). Under the selective pressure of FOM usage, these strains might acquire FOM resistance more easily. In the present study, cross-resistance of strains with reduced FOM susceptibility to other antimicrobial drugs was not significantly higher than in other strains, and these strains were not concentrating on specific genotypes.

Based on previous reports, acquisition of FOM-modifying enzymes (encoded by fos genes) and mutations in murA gene results in resistance, that is, surpass of breakpoints, to FOM [18, 19, 28]. The present study did not identify such strains. Another resistance mechanism is altered FOM incorporation into bacterial cells. The G6P and G3P transporters contribute to incorporation of FOM into cells [13, 14]. Loss of function or decreased expression levels of them leads to a reduction of FOM susceptibility [18, 29, 39]. We found that loss of UhpT (G6P transporter) activity is more dominant than that of GlpT (G3P transporter) in strains with decreased FOM susceptibility. In resistant (>128 [micro]g/mL) and intermediate (128 [micro]g/mL) strains, we noted amino acid deletion in the respective encoded proteins and no PCR amplification of the transporter-related genes (Table 3). In strains with FOM MICs between 8 and 64 [micro]g/mL, gene mutation(s) leading to alternations of amino acid residues were found; however, it was unclear whether these contributed to the reduced susceptibility. Among the ten strains with reduced susceptibility, nine strains did not grow on G6P-supplemented M9 minimum salt agar. This suggested that in these nine strains G6P-induced UhpT function was attenuated. We found several mutations in cyaA and ptsI in some of these strains. Dysfunction of CyaA and PtsI leads to decrease in intracellular concentration of cAMP and insufficient expression of GlpT and UhpT [16, 17, 31]. Only two strains (SRE91 and SRE252) with reduced susceptibility to FOM showed that MIC was decreased by the exogenous addition of cAMP, and these strains did not grow in M9 medium supplement with G3P. Certainly, SRE252 defected cyaA; however, SRE91 did not share any mutations in cyaA and pstl. Thus reduced susceptibility to FOM in the other strains was not explained by the insufficient intracellular concentration of cAMP caused by dysfunction of cyaA and pstl. The mutations in these genes found in this study (Table 3) seemed to scarcely relate with dysfunction of cAMP synthesis.

In conclusion, FOM resistance occurs with low frequency and is independent of resistance to other antimicrobials in E. coli clinical isolates from Japan. On the other hand, we identified strains with decreased FOM susceptibility. Most of them displayed fluctuated activity of the G6P transporter UhpT. However, G6P transporter function was altered even though the G6P-induced uhpT expression and amino acid sequence of UhpT were preserved in one strain (FOM MIC 8 [micro]g/mL). Another strain (FOM MIC 32 [micro]g/mL) displayed reduced susceptibility to FOM and no alteration of MIC in the presence and absence of G6P, even though G6P-induced uhpT expression, amino acid sequence of UhpT, and growth on G6P-supplemented M9 minimum salt agar were preserved. The exact molecular mechanism of the reduced susceptibility of these strains remains unclear and requires further evaluation.

http://dx.doi.org/10.1155/2017/5470241

Competing Interests

The authors declare no competing interests.

Acknowledgments

The authors thank Osamu Kuwahara (Sapporo Clinical Laboratory) for the provision of E. coli clinical isolates. This study was partly supported by a Grant-in-Aid for Scientific Research (15H06521) from Japan Society for the Promotion of Science and a grant from Yuasa Memorial Foundation.

References

[1] WHO, "Antimicrobial resistance: global report on surveillance 2014," 2014, http://www.who.int/drugresistance/documents/surveillancereport/en/.

[2] M. E. Falagas and D. E. Karageorgopoulos, "Extended-spectrum [beta]-lactamase-producing organisms," Journal of Hospital Infection, vol. 73, no. 4, pp. 345-354, 2009.

[3] J. D. D. Pitout, "Extraintestinal pathogenic Escherichia coli: an update on antimicrobial resistance, laboratory diagnosis and treatment," Expert Review of Anti-Infective Therapy, vol. 10, no. 10, pp. 1165-1176, 2012.

[4] S. Yokota, T. Sato, T. Okubo et al., "Prevalence of fluoroquinolone-resistant Escherichia coli O25:H4-ST131 (CTX-M15-nonproducing) strains isolated in Japan," Chemotherapy, vol. 58, no. 1, pp. 52-59, 2012.

[5] N. Tsukamoto, Y. Ohkoshi, T. Okubo et al., "High prevalence of cross-resistance to aminoglycosides in fluoroquinolone-resistant Escherichia coli clinical isolates," Chemotherapy, vol. 59, no. 5, pp. 379-384, 2014.

[6] H. Giamarellou and G. Poulakou, "Multidrug-resistant gram-negative infections: what are the treatment options?" Drugs, vol. 69, no. 14, pp. 1879-1901, 2009.

[7] M. E. Falagas, A. C. Kastoris, A. M. Kapaskelis, and D. E. Karageorgopoulos, "Fosfomycin for the treatment of multidrugresistant, including extended-spectrum [beta]-lactamase producing, Enterobacteriaceae infections: a systematic review," The Lancet Infectious Diseases, vol. 10, no. 1, pp. 43-50, 2010.

[8] A. Schaeffer, "Infections of the urinary tract," in Campbell-Walsh Urology, A. Wein, L. Kavoussi, A. Novick, A. Partin, and C. Peters, Eds., pp. 223-303, Elsevier, Philadelphia, Pa, USA, 9th edition, 2007.

[9] K. Ishikawa, R. Hamasuna, S. Uehara et al., "Japanese nationwide surveillance in 2011 of antibacterial susceptibility patterns of clinical isolates from complicated urinary tract infection cases," Journal of Infection and Chemotherapy, vol. 21, no. 9, pp. 623-633, 2015.

[10] D. N. Gilbert, H. F. Chambers, G. M. Eliopoulos, and M. S. Saag, The Sanford Guide to Antimicrobial Therapy 2015, Antimicrobial Therapy, Sperryville, Va, USA, 45th edition, 2015.

[11] The Japanese Association for Infectious Diseases and Japan Society of Chemotherapy, The JAID/JSC Guide to Clinical Management of Infectious Diseases 2014, The Japanese Association for Infectious Diseases/Japan Society of Chemotherapy, Tokyo, Japan, 2014 (Japanese).

[12] E. D. Brown, E. I. Vivas, C. T. Walsh, and R. Kolter, "MurA (MurZ), the enzyme that catalyzes the first committed step in peptidoglycan biosynthesis, is essential in Escherichia coli" Journal of Bacteriology, vol. 177, no. 14, pp. 4194-4197, 1995.

[13] F. M. Kahan, J. S. Kahan, P. J. Cassidy, and H. Kropp, "The mechanism of action of fosfomycin (phosphonomycin)," Annals of the New York Academy of Sciences, vol. 235, no. 1, pp. 364-386, 1974.

[14] M. J. Lemieux, Y. Huang, and D.-N. Wang, "Glycerol-3-phosphate transporter of Escherichia coli: structure, function and regulation," Research in Microbiology, vol. 155, no. 8, pp. 623-629, 2004.

[15] H. H. Winkler, "Kinetics of exogenous induction of the hexose-6-phosphate transport system of Escherichia coli" Journal of Bacteriology, vol. 107, no. 1, pp. 74-78, 1971.

[16] T. J. Merkel, J. L. Dahl, R. H. Ebright, and R. J. Kadner, "Transcription activation at the Escherichia coli uhpT promoter bythe catabolite gene activatorprotein" Journal of Bacteriology, vol. 177, no. 7, pp. 1712-1718, 1995.

[17] D. T. Verhamme, P. W. Postma, W. Crielaard, and K. J. Hellingwerf, "Cooperativity in signal transfer through the Uhp system of Escherichia coli" Journal of Bacteriology, vol. 184, no. 15, pp. 4205-4210, 2002.

[18] S. Takahata, T. Ida, T. Hiraishi et al., "Molecular mechanisms of fosfomycin resistance in clinical isolates of Escherichia coli" International Journal of Antimicrobial Agents, vol. 35, no. 4, pp. 333-337, 2010.

[19] J. Wachino, K. Yamane, S. Suzuki, K. Kimura, and Y. Arakawa, "Prevalence of fosfomycin resistance among CTX-M-producing Escherichia coli clinical isolates in Japan and identification of novel plasmid-mediated fosfomycin-modifying enzymes," Antimicrobial Agents and Chemotherapy, vol. 54, no. 7, pp. 3061-3064, 2010.

[20] K. Kurabayashi, Y. Hirakawa, K. Tanimoto, H. Tomita, and H. Hirakawa, "Role of the CpxAR two-component signal transduction system in control of fosfomycin resistance and carbon substrate uptake," Journal of Bacteriology, vol. 196, no. 2, pp. 248-256, 2014.

[21] P. Arca, G. Reguera, and C. Hardisson, "Plasmid-encoded fosfomycin resistance in bacteria isolated from the urinary tract in a multicentre survey," Journal of Antimicrobial Chemotherapy, vol. 40, no. 3, pp. 393-399,1997

[22] J. Hou, X. Huang, Y. Deng et al., "Dissemination of the fosfomycin resistance gene fosA3 with CTX-M [beta]-lactamase genes and rmtB carried on incfII plasmids among Escherichia coli isolates from pets in China," Antimicrobial Agents and Chemotherapy, vol. 56, no. 4, pp. 2135-2138, 2012.

[23] S.-Y. Lee, Y.-J. Park, J. K. Yu et al., "Prevalence of acquired fosfomycin resistance among extended-spectrum [beta]-lactamase-producing Escherichia coli and Klebsiella pneumoniae clinical isolates in Korea and IS26-composite transposon surrounding fosA3" Journal of Antimicrobial Chemotherapy, vol. 67, no. 12, Article ID dks319, pp. 2843-2847, 2012.

[24] P. L. Ho, J. Chan, W. U. Lo et al., "Prevalence and molecular epidemiology of plasmid-mediated fosfomycin resistance genes among blood and urinary Escherichia coli isolates," Journal of Medical Microbiology, vol. 62, no. 11, pp. 1707-1713, 2013.

[25] G. Nakamura, J. Wachino, N. Sato et al., "Practical agar-based disk potentiation test for detection of fosfomycin-nonsusceptible Escherichia coli clinical isolates producing glutathione S-transferases," Journal of Clinical Microbiology, vol. 52, no. 9, pp. 3175-3179, 2014.

[26] Y. Ma, X. Xu, Q. Guo, P. Wang, W. Wang, and M. Wang, "Characterization of fosA5, a new plasmid-mediated fosfomycin resistance gene in Escherichia coli" Letters in Applied Microbiology, vol. 60, no. 3, pp. 259-264, 2015.

[27] Y. Li, B. Zheng, Y. Li, S. Zhu, F. Xue, and J. Liu, "Antimicrobial susceptibility and molecular mechanisms of fosfomycin resistance in clinical Escherichia coli isolates in mainland China," PLoS ONE, vol. 10, no. 8, Article ID e0135269, 2015.

[28] S.-P. Tseng, S.-F. Wang, C.-Y. Kuo et al., "Characterization of fosfomycin resistant extended-spectrum [beta]-lactamase-producing Escherichia coli isolates from human and pig in Taiwan," PLoS ONE, vol. 10, no. 8, Article ID e0135864, 2015.

[29] A. I. Nilsson, O. G. Berg, O. Aspevall, G. Kahlmeter, and D. I. Andersson, "Biological costs and mechanisms of fosfomycin resistance in Escherichia coli" Antimicrobial Agents and Chemotherapy, vol. 47, no. 9, pp. 2850-2858, 2003.

[30] J. C. Cordaro, T. Melton, J. P. Stratis et al., "Fosfomycin resistance: selection method for internal and extended deletions of the phosphoenolpyruvate:sugar phosphotransferase genes of Salmonella typhimurium" Journal of Bacteriology, vol. 128, no. 3, pp. 785-793, 1976.

[31] Y. Sakamoto, S. Furukawa, H. Ogihara, and M. Yamasaki, "Fosmidomycin resistance in adenylate cyclase deficient (cya) mutants of Escherichia coli" Bioscience, Biotechnology and Biochemistry, vol. 67, no. 9, pp. 2030-2033, 2003.

[32] G. Kahlmeter and H. O. Poulsen, "Antimicrobial susceptibility of Escherichia coli from community-acquired urinary tract infections in Europe: the ECO-SENS study revisited," International Journal of Antimicrobial Agents, vol. 39, no. 1, pp. 45-51, 2012.

[33] D. E. Karageorgopoulos, R. Wang, X.-H. Yu, and M. E. Falagas, "Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in gram-negative pathogens," Journal of Antimicrobial Chemotherapy, vol. 67, no. 2, pp. 255-268, 2012.

[34] Clinical and Laboratory Standards Institute, Performance Standards for Antimicrobial Susceptibility Testing, 22nd Information Supplement, M100-S22, CLSI, Wayne, Pa, USA, 2012.

[35] O. Clermont, J. R. Johnson, M. Menard, and E. Denamur, "Determination of Escherichia coli O types by allele-specific polymerase chain reaction: application to the O types involved in human septicemia," Diagnostic Microbiology and Infectious Disease, vol. 57, no. 2, pp. 129-136, 2007

[36] D. Li, B. Liu, M. Chen et al., "A multiplex PCR method to detect 14 Escherichia coli serogroups associated with urinary tract infections," Journal of Microbiological Methods, vol. 82, no. 1, pp. 71-77, 2010.

[37] O. Clermont, S. Bonacorsi, and E. Bingen, "Rapid and simple determination of the Escherichia coli phylogenetic group," Applied and Environmental Microbiology, vol. 66, no. 10, pp. 4555-4558, 2000.

[38] S. Y. Tartof, O. D. Solberg, A. R. Manges, and L. W. Riley, "Analysis of a uropathogenic Escherichia coli clonal group by multilocus sequence typing," Journal of Clinical Microbiology, vol. 43, no. 12, pp. 5860-5864, 2005.

[39] R. J. Kadner and H. H. Winkler, "Isolation and characterization of mutations affecting the transport of hexose phosphates in Escherichia coliJournal of Bacteriology, vol. 113, no. 2, pp. 895-900, 1973.

Yasuo Ohkoshi, (1,2) Toyotaka Sato, (1) Yuuki Suzuki, (1) Soh Yamamoto, (1) Tsukasa Shiraishi, (1) Noriko Ogasawara, (1) and Shin-ichi Yokota (1)

(1) Department of Microbiology, Sapporo Medical University School of Medicine, Chuo-ku, Sapporo 060-8556, Japan

(2) Department of Clinical Laboratory, NTT East Sapporo Hospital, Chuo-ku, Sapporo 060-0061, Japan

Correspondence should be addressed to Shin-ichi Yokota; syokota@sapmed.ac.jp

Received 15 July 2016; Revised 22 December 2016; Accepted 27 December 2016; Published 19 January 2017

Academic Editor: Yun-Peng Chao

Caption: Figure 2: Induced expression levels of uhpT expression by the addition of G6P. Nine clinical isolates with reduced susceptibility to FOM; six susceptible clinical isolates and one standard strain are included. Data used to generate this figure are given in Table 2. Statistical significance was determined by Mann-Whitney test. (a) Comparison of strains not grown (-) or strains grown (+) in M9 minimum salt solution containing G6P. (b) Comparison of strains with FOM MIC [greater than or equal to] 8 [micro]g/mL or [less than or equal to]4 [micro]g/mL.
Table 1: PCR and real-time RT-PCR primers used in this study.

Primer                   Sequence (5'-3')       Reference

murA-full (a)    F     AAACAGCAGACGGTCTATGG       [18]
                 R   CCAT GAGTTTAT CGACAGAACG
glpT-full        F    GCGAGTCGCGAGTTTTCATTG       [18]
                 R     GGCAAATATCCACTGGCACC
uhpT-full        F     TTTTTGAACGCCCAGACACC       [18]
                 R     AGTCAGGGGCTATTTGATGG
uhpT-partial     F     ATGCTGGCTTTCTTAAACC        [19]
                 R     TTATGCCACTGTCAACTGC
uhpA-full        F     GATCGCGGTGTTTTTTCAG
                 R     GATACTCCACAGGCAAAACC       [18]
uhpA-partial     F     ATCACCGTTGCCCTTATAGA       [19]
                 R      TCACCAGCCATCAAACAT
ptsI-full        F     GAAAGCGGTTGAACATCTGG       [18]
                 R     TCCTTCTTGTCGTCGGAAAC
cyaA-full        F     AACCAGGCGCGAAAAGTGG        [18]
                 R     ACCTTCTGGGATTTGCTGG
rpoD-qPCR        F      CAAGCCGTGGTCGGAAAA        [20]
                 R      GGGCGCGATGCACTTCT
uhpT-qPCR        F      AAGCCGACCCTGGACCTT        [20]
                 R    ACGGTTTGAACCACATTTTGC

(a) Primers designated "full" were used for direct sequencing, and
"qPCR" were used for real-time RT-PCR.

Table 2: Antibiotic susceptibility and the presence of ESBL genes in
E.coli strains with FOM MIC [greater than or equal to] 8 [micro]g/mL.

Strains         Fosfomycin                  Levofloxacin
             ([greater than or           ([greater than or
              equal to]128)b              equal to]4) (b)

SRE257            1024 *            [less than or equal to]0.125
SRE91              128 #                        32 *
SRE49              128 #                        16 *
SRE54               64             [greater than or equal to] 64 *
SRE237              64              [less than or equal to] 0.125
SRE29               32                          16 *
SRE252              32                          0.5
SRE280              32              [less than or equal to] 0.125
SRE18               16                          32 *
SRE253               8              [less than or equal to] 0.125

                    MIC ([micro]g/mL)
Strains                Gentamicin                   Imipenem
                    ([greater than or           ([greater than or
                     equal to]8) (b)             equal to]2) (b)

SRE257                      1                         0.125
SRE91                       4                         0.25
SRE49                       2                         0.125
SRE54        [greater than or equal to] 64 *          0.125
SRE237                      4                         0.125
SRE29        [greater than or equal to] 64 *          0.125
SRE252                      2                         0.125
SRE280                     8 *                         0.5
SRE18                       2                         0.125
SRE253                      4                          0.5

Strains         Ceftazidime      ESBL (a) gene
             ([greater than or
              equal to]8) (b)

SRE257             0.125              --
SRE91              0.125              --
SRE49              0.25               --
SRE54                2              CTX-M14
SRE237             0.125              --
SRE29              0.125              --
SRE252             0.125              --
SRE280             0.125              --
SRE18                2              CTX-M2
SRE253             0.125              --

(a) ESBL: extended spectrum [beta]-lactamase.

(b) Breakpoints ([micro]g/mL) are according to CLSI.

* Resistant.

# Intermediate.

Table 3: Characteristics of E. coli strains used in the study.

                                Phylo-              MIC (a)
                       Sero-    genetic          ([micro]g/mL)
Strain    Specimen     group     group    MLST

                                                 G6P -    G6P +

SRE257     Urine        O1        B2       95    1024    1024

SRE91    Aspiration     O1         D      648     128    128
            tube

SRE49      Urine      025b:H4     B2      131    128     128
SRE54      Urine      025b:H4     B2      131    64      64

SRE237     Urine      025b:H4     B2      131    64      64
SRE29      Urine      025b:H4     B2      131    32      32
SRE252     Urine       025a        D       73    32      32
SRE280    Ascites       012        D      1486   32      3
SRE18      Urine        ND         D      405    16      16
SRE253     Urine        018       B2       95    8       8
SRE40    Decubitus     025a        D      501    32      0.5
SRE41     Catheter      Ol         D      648    8       0.5
           urine
SRE110    Catheter    025b:H4     B2      131    8       0.5
           urine
SRE205     Urine        ND         A      131    8       0.5
SRE227      Pus         Ol        B2       95    8       0.5
SRE30      Urine        Ol         D      648    8       0.25
ATCC                    NT        NT             32      0.5
25922

                   Growth on      uhpT         Amino acid residue
                    M9 agar     expression   alternations in proteins
                 supplemented   induced by    encoded by glpT, ptsI,
Strain               with:       G6P (b)      cyaA, murA, uhpA, and
                                                 uhpT genes (c)

         G6P+    G3P    G6P                    cyaA        glpT
         cAMP+

SRE257   1024     +      -        1.24          --          --

SRE91     32      -      -        3.78          --        155~158
                                                         deletion
                                                         Phel76Leu
SRE49     128     +      -         NT       His716Leu       --
SRE54     64      +      -        1.59      His716Leu       --

SRE237    64      +      -        1.59      His716Leu       --
SRE29     32      +      +      1226.22         --          --
SRE252     4      -      -        3.68          ND       Ilel71Thr
SRE280    32      +      -        0.56      Serl42Asn       --
SRE18     16      +      -        2.22          --          --
SRE253     8      -      -       198.09     His716Leu       --
SRE40     NT      +      +       284.05
SRE41     NT      +      +       328.56

SRE110    NT      +      +       190.02

SRE205    NT      +      +       734.19
SRE227    NT      +      +       247.28
SRE30     NT      +      +       719.08
ATCC      NT      +      +
25922                            308.69

           Amino acid residue alternations
          in proteins encoded by glpT, ptsI,
         cyaA, murA, uhpA, and uhpT genes (c)
Strain

         murA     ptsI        uhpA     uhpT

SRE257    --    Val399Leu   163-188     --
                            deletion
SRE91     --       --
                            ThrSAla     --

SRE49     --    Lys410Arg      ND       ND
SRE54     --    Ala443Thr      --       --
                Gly452Asp
SRE237    --       --          --       --
SRE29     --       --          --       --
SRE252    --    Lysl45Asn      --       --
SRE280    --       --          --       --
SRE18     --       --       Metllle     --
SRE253    --       --          --       --
SRE40
SRE41

SRE110

SRE205
SRE227
SRE30
ATCC
25922

(a) FOM MICs were determined in the presence (+) or absence (-) of
glucose-6-phosphate (G6P) and/or cAMP.

(b) E. coli cells were incubated in M9 minimum salt solution in the
presence or absence of G6P The uhpT mRNA levels were determined by

real-time RT-PCR, and the data were normalized to rpoD mRNA levels.
Induction of uhpT expression by G6P was calculated by dividing the
uhpT mRNA level in the presence of G6P by the uhpT mRNA level in the
absence of G6P.

(c) Amino acid mutations found only in strains with reduced FOM
susceptibility (MIC [greater than or equal to] 8 [micro]g/mL) compared
with strains with FOM MIC < 1 [micro]g/mL.

ND: not detected. NT: not tested.

Figure 1: Distribution of fosfomycin MICs of the E. coli clinical
isolates. The breakpoint is according to CLSI guideline. S:
susceptible, I: intermediate, and R: resistant.

MIC ([micro]g/mL)

0.125               0
0.25                12
0.5                 82
1                   89
2                   18
4                   0
8                   1
16                  1
32                  3
64                  2
128                 2
256                 0
512                 0
1024                1
2048                0

Note: Table made from bar graph.
COPYRIGHT 2017 Hindawi Limited
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Research Article
Author:Ohkoshi, Yasuo; Sato, Toyotaka; Suzuki, Yuuki; Yamamoto, Soh; Shiraishi, Tsukasa; Ogasawara, Noriko;
Publication:BioMed Research International
Article Type:Report
Geographic Code:9JAPA
Date:Jan 1, 2017
Words:5050
Previous Article:Solid Pseudopapillary Neoplasm of the Pancreas: Clinicopathologic Feature, Risk Factors of Malignancy, and Survival Analysis of 53 Cases from a...
Next Article:Optimization of Catheter Based rtPA Thrombolysis in a Novel In Vitro Clot Model for Intracerebral Hemorrhage.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters